Skip to main content
TipRanks
Go Ultimate75% OFF

Travere Therapeutics (17R) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

17R Analyst Ratings

Strong Buy
12Ratings
11Buy1Hold0Sell
Based on 12 analysts giving stock ratings to Travere Therapeutics in the past 3 months

17R Stock 12 Month Forecast

€66.06▲(100.19% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Travere Therapeutics in the last 3 months. The average price target is EUR 66.06 with a high forecast of EUR 78.02 and a low forecast of EUR 56.25. The average price target represents a 100.19% change from the last price of EUR 33.00.
Highest Price Target€78.02Average Price Target€66.06Lowest Price Target€56.25

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:17R
Price TargetArticle
Piper Sandler€61.69buy86.95%UpsideReiterated11/16/26
J.P. Morgan€81.65→€78.02buy136.43%UpsideReiterated11/06/26
Leerink Partners Analyst forecast on DE:17RUnknown AnalystNot RankedLeerink Partners€70.77→€60.79buy84.20%UpsideReiterated11/05/26
Canaccord Genuity€63.51→€65.32buy97.95%UpsideReiterated11/04/26
H.C. Wainwright€60.79buy84.20%UpsideReiterated11/03/26
Wells Fargo€72.58buy119.94%UpsideAssigned11/03/26
Cantor Fitzgerald―buy―Reiterated11/03/26
Wedbush€68.95buy108.94%UpsideReiterated11/03/26
Stifel Nicolaus€56.25hold70.45%UpsideReiterated11/03/26
Bank of America Securities€64.41→€63.51buy92.45%UpsideReiterated11/03/26
Guggenheim€80.75→€70.77buy114.44%UpsideReiterated11/03/26
TD Cowen€68.04buy106.19%UpsideReiterated11/02/26
Evercore ISI€61.69→€70.77buy114.44%UpsideReiterated08/10/26
Citi€63.51→€77.12buy133.69%UpsideReiterated08/06/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
QUITAchieve Life Sciences
SLDBSolid Biosciences
RDNTRadnet
PTGXProtagonist Therapeutics
HROWHarrow Health

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Travere Therapeutics

3 Months
Jason Zemansky
Jason ZemanskyBank of America Securities
Success Rate15/23 ratings generated profit
65%
Average Return
+23.50%

Copying Jason Zemansky's trades and holding each position for 3 Months would result in 65.22% of your transactions generating a profit, with an average return of +23.50% per trade.

1 Year
Jason Zemansky
Jason ZemanskyBank of America Securities
Success Rate19/23 ratings generated profit
83%
Average Return
+71.79%

Copying Jason Zemansky's trades and holding each position for 1 Year would result in 82.61% of your transactions generating a profit, with an average return of +71.79% per trade.

2 Years
Joseph Schwartz
Joseph SchwartzLeerink Partners
Success Rate22/25 ratings generated profit
88%
Average Return
+237.40%

Copying Joseph Schwartz's trades and holding each position for 2 Years would result in 88.00% of your transactions generating a profit, with an average return of +237.40% per trade.

17R Analyst Recommendation Trends

020406080Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for 17R
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy00027
Buy3433232215
Hold12221
Sell00000
Strong Sell00000
total3535252623

In the current month, 17R has received 22 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 17R average Analyst price target in the past 3 months is 66.06.

17R Financial Forecast

€-2€-1.25€-0.5€0.25€1Q1 2026Q3 2026Q4 2026
High€0.55
Consensus€0.39
Low€0.27

17R Earnings Forecast

Next quarter’s earnings estimate for 17R is EUR 0.39 with a range of EUR 0.27 to EUR 0.55. The previous quarter’s EPS was -EUR 0.49. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

€113.5M€151.3M€189.2M€227.1M€264.9MQ1 2026Q3 2026Q4 2026
High€265M
Consensus€221M
Low€195M

17R Sales Forecast

Next quarter’s sales forecast for 17R is EUR 220.79M with a range of EUR 194.76M to EUR 264.94M. The previous quarter’s sales results were EUR 200.32M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

17R Stock Forecast FAQ

What is DE:17R’s average 12-month price target, according to analysts?
Based on analyst ratings, Travere Therapeutics’s 12-month average price target is €66.06.
What is DE:17R’s upside potential, based on the analysts’ average price target?
Travere Therapeutics has 100.19% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Travere Therapeutics a Buy, Sell or Hold?
Travere Therapeutics has a consensus rating of Strong Buy, which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
What is Travere Therapeutics’s share price target?
The average share price target for Travere Therapeutics is €66.06. This is based on 12 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €78.02, and the lowest forecast is €56.25. The average share price target represents a 100.19% increase from the current price of €33.
What do analysts say about Travere Therapeutics?
Travere Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Street analysts.
How can I buy shares of Travere Therapeutics?
To buy shares of DE:17R, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.